Hosted on MSN1d
Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment
retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3). This designation marks a significant step forward in Ocugen ...
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST
Ocugen (OCGN) announced that the European Medicines Agency, EMA, has granted orphan medicinal product designation for OCU410ST for the ...
Medscape21d
The Genetics of Hereditary Retinopathies and Optic Neuropathies
For mere clinical classification purposes, rod-cone dystrophies can be broadly divided into early onset forms (i.e., which are either consistently severe from birth with little progression ...
Ocugen Receives Orphan Medicinal Product Designation From EMA For OCU410ST
Ocugen, Inc. (OCGN) announced the European Medicines Agency has granted orphan medicinal product designation for OCU410ST for the ...